Cancer News
OncoLink Cancer News - HealthDay


Pill Effects on Breast, Ovarian CA Same in High-Risk Women

Tuesday, October 22, 2013 (Last Updated: 10/23/2013)

TUESDAY, Oct. 22 (HealthDay News) -- Among women who are BRCA1/2 mutation carriers, the associations between ever use of oral contraceptives (OCs) and ovarian and breast cancers are similar to those observed in the general population, according to research published online Oct. 21 in the Journal of Clinical Oncology.

Patricia G. Moorman, Ph.D., of Duke University in Durham, N.C., and colleagues performed a systematic review of the literature and meta-analysis to estimate the risks of breast cancer and ovarian cancer associated with use of OCs in women at increased risk.

The researchers note that meta-analysis showed a significant inverse association between OC use and ovarian cancer (odds ratio [OR], 0.58; 95 percent confidence interval [CI], 0.46 to 0.73) and a non-significant association between OC use and breast cancer (OR, 1.21; 95 percent CI, 0.93 to 1.58) for BRCA1 and BRCA2 mutation carriers combined. Similar patterns were observed when mutation carriers were analyzed separately.

"Our analyses suggest that associations between ever use of OCs and ovarian and breast cancer among women who are BRCA1 or BRCA2 mutation carriers are similar to those reported for the general population," the authors write.

Abstract
Full Text (subscription or payment may be required)

Specialties Gastroenterology

Copyright © 2013 HealthDay. All rights reserved.


I Wish You Knew

Pain management in cancer care - are patients getting what they need?

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More